Trichosanthin enhances sensitivity of non-small cell lung cancer (NSCLC) TRAIL-resistance cells



Supplemental Figure S1. The authentication of the A549 cell line. PCR was implemented with STR Multi-amplification KIT (PowerPlexTM 16HS System). No loci had tri-alleles or tetra-alleles. Contamination of other human cells was not detected. 100% matched cell line A549 were found in both ATCC and DSMZ data banks. The cell STR profiling passed on 2017/3/8.



Supplemental Figure S2. The authentication of the H1975 cell line. PCR was implemented with STR Multi-amplification KIT (PowerPlexTM 16HS System). No loci had tri-alleles or tetra-alleles. Contamination of other human cells was not detected. 100% matched cell line H1975 were found in both ATCC and DSMZ data banks. The cell STR profiling passed on 2017/3/8.



Supplemental Figure S3. The authentication of the H1299 cell line. PCR was implemented with STR Multi-amplification KIT (PowerPlexTM 16HS System). No loci had tri-alleles or tetra-alleles. Contamination of other human cells was not detected. 100% matched cell line H1299 were found in both ATCC and DSMZ data banks. The cell STR profiling passed on 2017/3/8.



Supplemental Figure S4. Effects of TCS and TRAIL on the proliferation of NSCLC cells. (A) The cells were incubated with different concentrations of TCS and TRAIL at a constant ratio of 1:10. The cell viability of H1299, A549 and H1975 were determined by CCK8. **(B)** Combination index (CI) values of each drug fraction were calculated using the Chou-Talalay method in H1299, A549 and H1975 cells respectively.



Supplemental Figure S5. The combination of TCS and TRAIL upregulated Ecadherin expression. (A) Representative images of immunofluorescence for Ecadherin in H1299 cells treated with or without TCS and TRAIL. The original magnification was 400X. The scale bar: 25 μ m. (B) The combination of TCS and TRAIL increased the immunofluorescent intensity of E-cadherin. ** p < 0.01.



Supplemental Figure S6. The combination of TCS and TRAIL upregulated the transcription of DR4 and DR5. (A) RT-PCR analysis for DR4 and DR5 after treatment with 50 ng/ml TRAIL or / and 40 μ g/ml TCS for 48 h. GAPDH was used as an internal control. (B-C) The combination of TCS and TRAIL increased the mRNA levels of DR4 and DR5. ** p < 0.01.



Registered Office: Elsevier Ltd The Boulevard, Langford Lane, Kidlington, OX5 1GB, UK. Registration No. 331566771

To whom it may concern

The paper "Trichosanthin enhances sensitivity of non-small cell lung cancer (NSCLC) TRAIL-resistant cells" by Chengcheng You, Yingming Sun, Shiyu Zhang, Guiliang Tang, Nannan Zhang, Chunyang Li, Xiaoli Tian, Shijing Ma, Yuan Luo, Wenjie Sun, Feng Wang, Xuefeng Liu, Yan Gong, Yu Xiao, Junhong Zhang , Conghua Xie was edited by Elsevier Language Editing Services.

Kind regards,

Elsevier Webshop Support

Supplemental Figure S7. The certificate issued by the Elsevier editing service.

Antigen	Species Antibody	Method	Dilution	Supplier
	Raise in			
Ki-67, human	Rabbit, monoclonal	IF	1:200	Abcam, Cat. #ab16667
GAPDH, human	Rabbit, polyclonal	WB	1:5,000	Proteintech, Cat. #10494-1-AP
BCL-2, human	Rabbit, monoclonal	WB	1:2,000	Abclonal, Cat. # A2212
BAX, human	Rabbit, monoclonal	WB	1:1,000	Proteintech, Cat. #50599-2-Ig
PARP, human	Rabbit, monoclonal	WB	1:2,000	CST, Cat. #9532
FADD, human	Rabbit, polyclonal	WB	1:1,000	Proteintech, Cat. #14906-1-AP
Caspase 8, human	Rabbit, polyclonal	WB	1:1,500	Proteintech, Cat. #13423-1-AP
Caspase 3, human	Rabbit, polyclonal	WB	1:1,500	Proteintech, Cat. #19677-1-AP
MMP-2, human	Rabbit, polyclonal	WB	1:1,500	Proteintech, Cat. #10373-2-AP
MMP-9, human	Rabbit, monoclonal	WB	1:1,000	Proteintech, Cat. #10375-2-AP
ICAM-1, human	Rabbit, monoclonal	WB	1:1,500	Proteintech, Cat. #10831-1-AP
E-cadherin, human	Rabbit, monoclonal	WB	1:1,000	CST, Cat. #3195
E-cadherin, human	Rabbit, monoclonal	IF	1:1,00	CST, Cat. #3195
N-cadherin, human	Rabbit, polyclonal	WB	1:1,000	Proteintech, Cat. #22018-1-AP
Vimentin, human	Rabbit, monoclonal	WB	1:1,000	CST, Cat. #5741
CDK2, human	Rabbit, polyclonal	WB	1:1,500	Proteintech, Cat. #10122-1-AP
Cyclin D1, human	Rabbit, monoclonal	WB	1:1,000	CST, Cat. #2978
CCNE1, human	Rabbit, polyclonal	WB	1:1,500	Proteintech, Cat. #11554-1-AP
Cyclin A1 + Cyclin A2, human	Rabbit, monoclonal	WB	1:2,000	Abcam, Cat. #ab185619
P27, human	Rabbit, polyclonal	WB	1:1,200	Proteintech, Cat. #25614-1-AP
ATP1A1, human	Rabbit, polyclonal	WB	1:1,500	Proteintech, Cat. # 14418-1-AP
DR4, human	Rabbit, monoclonal	WB	1:1,000	CST, Cat. # 42533
DR5, human	Rabbit, monoclonal	WB	1:1,000	CST, Cat. # 8074
DR4, human	Rabbit, monoclonal	IF	1:100	CST, Cat. # 42533
DR5, human	Rabbit, monoclonal	IF	1:50	CST, Cat. # 8074
DR4, human	Rabbit, monoclonal	FC	1:50	CST, Cat. # 42533
DR5, human	Rabbit, monoclonal	FC	1:20	Bioss, Cat. # bs-7352R

Supplemental Table S1. List of primary antibodies used in this study.

IF: Immunofluorescence ; FC: Flow cytometry ; WB: Western blot.

Supplemental Table S2. List of secondary antibodies and DAP

Host	Method	Dilution	Supplier
Goat	WB	1:10,000	Proteintech, Cat. #SA00001-1
Goat	WB	1:10,000	Proteintech, Cat. #SA00001-2
Goat	IF	1:500	Proteintech, Cat. #SA00006-3
-	IF	1 µg/ml	Sigma, Cat. #D8417
Goat	IF, FC	1:100	Proteintech, Cat. #SA00003-2
Goat	IF, FC	1:100	Proteintech, Cat. #SA00009-2
	Host Goat Goat - Goat Goat	HostMethodGoatWBGoatIF-IFGoatIF, FCGoatIF, FC	Host Method Dilution Goat WB 1:10,000 Goat WB 1:10,000 Goat IF 1:500 - IF 1 μg/ml Goat IF, FC 1:100 Goat IF, FC 1:100

IF: Immunofluorescence; FC: Flow cytometry; WB: Western blot.